GlassScriptPhysician profile
William D Whitton
NPI 1790754307
$2,405.16
in general payments reported to CMS, 2019-2025
28 companies · $703 in 2025
The $703 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $44.13 · 2021: $30.24 · 2022: $306 · 2023: $517 · 2024: $564 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,783.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $501.06 | 2022-2025 | |
| Abbvie INC. | $427.01 | 2021-2025 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $247.51 | 2020-2025 | Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.92 | 2019-2020 | |
| Axsome Therapeutics, INC. | $102.50 | 2023-2025 | Auvelity, Symbravo, Sunosi |
| Novo Nordisk INC | $91.33 | 2023-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $81.48 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $75.23 | 2025 | Veozah |
| Inspire Medical Systems, INC. | $67.79 | 2025 | Inspire |
| Mayne Pharma Commercial LLC | $66.08 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $59.22 | 2022 | |
| Abbott Laboratories | $50.33 | 2024-2025 | Freestyle Libre 3 |
| Genentech USA, INC. | $48.21 | 2019 | |
| Shield Therapeutics INC | $47.67 | 2023-2024 | Accrufer |
| Medtronic, INC. | $41.80 | 2023 | Intellis Adaptivestim |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $41.25 | 2024-2025 | Rexulti |
| Revance Therapeutics, INC. | $41.15 | 2025 | Daxxify |
| Galderma Laboratories, L.P. | $32.62 | 2021-2024 | Dysport |
| Novartis Pharmaceuticals Corporation | $29.98 | 2023-2024 | |
| Amgen INC. | $29.73 | 2022-2025 | Repatha, Otezla |
| Merz North America, INC. | $29.26 | 2019 | |
| Allergan, INC. | $28.55 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $22.82 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.71 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.72 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $16.29 | 2023 | Seglentis |
| Merck Sharp & Dohme LLC | $15.05 | 2023 | Verquvo, Steglujan, Steglatro |
| Amneal Pharmaceuticals LLC | $13.89 | 2025 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Whitton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.